
BEST AVAILABLE COPY 10 FINITE GDHSTP human ANX2 SYGGERENKCPT Danio ANX2b 60 40 D A P R D A A A K human ANX2 Danio ANX2b Ε DA. 80 90 70 NAQ KQQ LKKS human ANX2 Danio ANX2b R 120 100 110 ETT PA QUY human ANX2 M RAST P Danio ANX2b QYDA 150 130 140 T N Q REPROREMENT AND A TOP OF THE PROPERTY OF human ANX2 NKE Danio ANX2b TDE.SLIE 180 160 170 DYN I S human ANX2 Danio ANX2b DLEKDI DTSGDF 200 210 190 L D AR T L T D G B WALLED human ANX2 Q S Danio ANX2b LY YE 240 220 230 human ANX2 Danio ANX2b 270 260 250 human ANX2 BK S TRIET Danio ANX2b FL EVKGDLE 300 290 280 WAY DIS MAKE KIG TR human ANX2 Danio ANX2b MKGK DK. 310 320 Y Y Y 関Q Q D 🖫 human ANX2 TES EHE Danio ANX2b EFKR TKGDYQ 360 340 350 CONTROL (SEQ ID NO:1) LL L G G D D human ANX2 Danio ANX2b FIG. IA



3/8




FIG. 2A




FIG. 2B

SUBSTITUTE SHEET (RULE 26)






FIG. 2C




FIG. 2D


FRAGMENT 1: MTSGYKXGTPEEXYAHXPE

FRAGMENT 2: EXDNDSINEXTLQXVH

FRAGMENT 3: LTLSYGGEXEPK FRAGMENT 4: RSLLKRSDIAFEYE FRAGMENT 5: VFEXYKRYSPXDL Caveolin 1-20 (SEQ ID NO.5)
Caveolin 34-49 (SEQ ID NO.6)
Annexin IIb 11-22 (SEQ ID NO.7)
Annexin IIb 63-76 (SEQ ID NO.8)
Annexin IIb 228-240 (SEQ ID NO.9)


FIG 2E

SUBSTITUTE SHEET (RULE 26)



6/8

BEST AVAILABLE COPY






FIG. 4

7/8

BES. ~OPY




FIG. 5A




FIG 5B **SUBSTITUTE SHEET (RULE 26)**




FIG. 5C